author-photo

Kristin Stephens

10

Papers

51

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

2017 Blood
Show All
- Source
- Cite
- Save
Citations (4)
425TiPA phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease

2013 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (34)
Vedolizumab Maintenance Therapy for Crohnʼs Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial: 1542

2012 The American Journal of Gastroenterology
Show All
- Source
- Cite
- Save
Citations (1)